Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers (PEER)

School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are educated about the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. PEER will evaluate a program to increase health and wellness and the use of SBHCs for primary and preventive care. If successful, PEER could significantly increase the use of SBHCs, and decrease HPV-associated cancers and, thus, reduce the burden of cancer in the United States.

Study Overview

• Status: Enrolling by invitation
• Conditions: School Health Services
• Intervention / Treatment: Behavioral: Mailers; Behavioral: Provider Materials; Behavioral: Peer-to-Peer Educational Sessions

• Study Type: Interventional
• Enrollment (Estimated): 4000
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Oregon
    • Portland, Oregon, United States, 97227
      • Kaiser Permanente Center for Health Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Aged 9-18
• New or established patients
• Flagged if due for an HPV vaccine

Exclusion Criteria:

- None

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control time (pre-implementation); All participating SBHCs offer routine HPV vaccination recommendations as part of clinical care and SBHC staff will continue to follow standard procedures to deliver these services. Further, all SBHCs have existing relationships with the affiliated schools, so the delivery of these healthcare services in the context of schools will not deviate from usual care.
Experimental: Intervention (post-implementation); Intervention components (mailers, provider materials, and peer-to-peer educational sessions) will be administered during the intervention portion of each cluster.	Behavioral: Mailers; Letter and fact sheet (infographic) mailed to caregivers of 9-14 year-olds and to teens 15-18, with optional phone call for "confidential patients" aged 15-18.; Behavioral: Provider Materials; Clinic team/staff training based on qualitative interviews, recommended strategies and evidence-based interventions. Training materials include FAQs and Smart phrases. FAQs and informational sheets containing the same content as the mailers distributed in clinic to teen SBHC patients and their caregivers.; Behavioral: Peer-to-Peer Educational Sessions; Educational sessions delivered in schools by OSBHA interns. Session content includes SBHC information and HPV awareness.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Vaccination for HPV (n of patients with HPV vaccination/n of patients eligible for vaccination)	Vaccination among eligible clinic patients, and time to vaccination	6 and 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rates of new patients to the clinic (n of new patients/n of established patients)	New patients seen (vs. prior seen pts.) - New patient characteristics (age, rural)	6 and 12 months
Rate of use of other SBHC services (primary care visits, wellness assessments) (n of patients with primary care visits/n of new and established patients)	Use of other SBHC services and visits among eligible clinic patients	6 and 12 months
Rate of vaccination for other adolescent vaccinations (COVID-19, flu, Meningitis, or uptick of other vax's (TDAP, MMR, etc.)) (n of patients with additional vaccination among new and eligible clinic patients)	Vaccination among eligible clinic patients, and time to vaccination	6 and 12 months

Collaborators and Investigators

• Sponsor: Kaiser Permanente
• Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
• Investigators: Principal Investigator: Amanda Petrik, PhD, Kaiser Permanente

Study record dates

Study Major Dates

• Study Start (Actual): January 12, 2026
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): June 1, 2029

Study Registration Dates

• First Submitted: February 6, 2026
• First Submitted That Met QC Criteria: February 13, 2026
• First Posted (Actual): February 17, 2026

Study Record Updates

• Last Update Posted (Actual): May 1, 2026
• Last Update Submitted That Met QC Criteria: April 24, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: R01MD019038-01A1 (U.S. NIH Grant/Contract); R01MD019038 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Deidentified data and accompanying data dictionaries will be stored for future sharing as anonymized data sets in a data repository per NIH data sharing requirements.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No